Evaluation of Subretinal Fluid Drainage Techniques During Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment-ELLIPSOID Study

Evaluation of Subretinal Fluid Drainage Techniques During Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment

This was a retrospective, consecutive, interventional, comparative clinical study looking at 300 consecutive patients (300 eyes) with primary macula-off rhegmatogenous retinal detachments (RRD). The study compared RRD drainage techniques and their final outcomes. The primary outcomes of this study were the visual acuity and outer retinal integrity following 23g RRD repair with drainage from peripheral retinal breaks (PRB), posterior retinotomy (PR), or perfluorocarbon liquid (PFCL).

There were 100 patients included in each of the three drainage groups. Visual acuity and spectral domain optical coherence tomography (SD-OCT) were performed preoperatively and performed at 3, 6, and 12 months postoperatively. Specifically on OCT, the discontinuity of the external limiting membrane, ellipsoid zone, and interdigitation zone were noted.

Baseline characteristics amongst the three groups were similar in regards to age, gender, time to presentation, lens status, size of detachment, and preoperative vision. There were no differences between gas tamponade used, amount of laser used, or postoperative complications between the groups.

In regards to single surgery success for retinal reattachment, the rates were 86% in the PRB group, 85% in the PR group, and 83% in the PFCL group (P=.9). Mean visual acuity at 1 year was greater with PRB and PR compared with PFCL (P=.002). There were discontinuities in the external limiting membrane in 26% of the PRB group, 24% in the PR group, and 44% in the PFCL group (P=.001). There were discontinuities in the ellipsoid zone in 29% of the PRB group, 31% of the PR group, and 49% of the PFCL group (P<.001). There were discontinuities in the interdigitation zone in 43% of the PRB group, 39% of the PR group, and 56% of the PFCL group (P=.004). There was cystoid macular edema (CME) noted in 28% of the PRB group, 39% of the PR group, and 46% of the PFCL group (P=.003). Epiretinal membrane (ERM) was noted in 64% of the PRB group, 90% of PR group, and 61% of PFCL group (P<.001).

In summary, the different drainage techniques showed different outcomes in regards to visual acuity, outer retinal SD-OCT characteristics, and CME/ERM formation. Drainage with PFCL was associated with worse visual acuity, greater risk of persistent outer retinal discontinuity, and greater risk of CME as compared to drainage with PRB or PR. PR had a greater risk of ERM formation. Drainage through PRB had the best outcomes overall.

There are limitations to the study. This is a retrospective study, and even though baseline characteristics between the groups were similar, bias could have played a part in choosing the surgical approach. There were multiple surgeons involved so some of the variation could be due to surgeon variation. Further prospective clinical trials could help to confirm the findings found in this clinical study.

In summary, this was an excellent study showing that drainage through PRB could have better visual and outer retinal anatomical outcomes at 1 year after primary mac-off RRD repair as compared to PR and PFCL.

Details
  • Overview

    January 2023: VBS Literature Update

    McKay BR, Bansal A, Kryshtalskyj M, Wong DT, Berger A, Muni RH. Evaluation of subretinal fluid drainage techniques during pars plana vitrectomy for primary rhegmatogenous retinal detachment-ELLIPSOID study. Am J Ophthalmol. 2022;241:227-237.

    Abstract by Priya Sharma Vakharia, MD

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the influence of different drainage techniques on visual acuity and outer retinal integrity in macula-off primary retinal detachment repair
    • Accreditation

       Provided by Evolve Medical Education

      Accreditation Statement
      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and Vit Buckle Society.  Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve Medical Education LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.

    • Faculty and Disclosures

      Priya Sharma Vakharia, MD

      Priya Sharma Vakharia, MD

      Retina Vitreous Associates of Florida
      Tampa Bay, FL


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Priya Sharma Vakharia, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Bausch + Lomb, Genentech, Gyroscope Therapeutics, Notal Vision, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, Annexon, AsclepiX Therapeutics, Bayer, Chengdu Kanghong, Biotech (PANDA Trial stopped 04/2021), EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron Pharmaceuticals, RegenxBio, and Unity. Speaker's Bureau: Bausch + Lomb, Genentech, and Heidelberg Engineering. Stock/Shareholder: Network Eye and Quad-C/Prism Vision Group.

      The Evolve staff and planners have no financial relationships with ineligible companies.
      Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Vit Buckle Society.

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Expiration Date:

    0.25 credits
    Completing the pre-test is required to access this content.
    Completing the pre-survey is required to view this content.

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free